TuHURA Biosciences (HURA) Competitors $4.48 +0.48 (+12.00%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends HURA vs. EOLS, RAPP, DNTH, AUTL, PRTA, OCS, CGEM, TECX, TRDA, and ABUSShould you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Evolus (EOLS), Rapport Therapeutics (RAPP), Dianthus Therapeutics (DNTH), Autolus Therapeutics (AUTL), Prothena (PRTA), Oculis (OCS), Cullinan Therapeutics (CGEM), Tectonic Therapeutic (TECX), Entrada Therapeutics (TRDA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. TuHURA Biosciences vs. Evolus Rapport Therapeutics Dianthus Therapeutics Autolus Therapeutics Prothena Oculis Cullinan Therapeutics Tectonic Therapeutic Entrada Therapeutics Arbutus Biopharma Evolus (NASDAQ:EOLS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Is EOLS or HURA more profitable? TuHURA Biosciences has a net margin of 0.00% compared to Evolus' net margin of -22.33%. TuHURA Biosciences' return on equity of 0.00% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.33% -847.60% -22.15% TuHURA Biosciences N/A N/A -152.88% Do insiders & institutionals have more ownership in EOLS or HURA? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 6.1% of Evolus shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, EOLS or HURA? Evolus has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Does the media prefer EOLS or HURA? In the previous week, TuHURA Biosciences had 6 more articles in the media than Evolus. MarketBeat recorded 7 mentions for TuHURA Biosciences and 1 mentions for Evolus. Evolus' average media sentiment score of 0.88 beat TuHURA Biosciences' score of 0.82 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in EOLS or HURA? Evolus received 350 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 72.58% of users gave Evolus an outperform vote. CompanyUnderperformOutperformEvolusOutperform Votes35272.58% Underperform Votes13327.42% TuHURA BiosciencesOutperform Votes2100.00% Underperform VotesNo Votes Which has better valuation & earnings, EOLS or HURA? TuHURA Biosciences has lower revenue, but higher earnings than Evolus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$248.33M2.78-$61.69M-$0.91-11.97TuHURA BiosciencesN/AN/A-$8.32MN/AN/A Do analysts prefer EOLS or HURA? Evolus currently has a consensus price target of $23.00, indicating a potential upside of 111.20%. TuHURA Biosciences has a consensus price target of $13.00, indicating a potential upside of 190.18%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryEvolus and TuHURA Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HURA vs. The Competition Export to ExcelMetricTuHURA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$189.44M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / SalesN/A195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book-1.095.104.794.78Net Income-$8.32M$151.51M$120.07M$225.60M7 Day Performance-9.13%-2.15%-1.89%-1.24%1 Month Performance32.94%-3.14%11.45%3.36%1 Year PerformanceN/A11.50%30.61%16.58% TuHURA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HURATuHURA BiosciencesN/A$4.48+12.0%$13.00+190.2%N/A$189.44MN/A0.00N/AAnalyst ForecastNews CoverageHigh Trading VolumeEOLSEvolus3.8237 of 5 stars$11.53+0.2%$23.00+99.5%+12.5%$730.08M$202.09M-12.73170RAPPRapport Therapeutics1.5171 of 5 stars$19.89+6.0%$35.00+76.0%N/A$727.58MN/A0.00N/ADNTHDianthus Therapeutics1.3337 of 5 stars$24.43+2.6%$46.43+90.0%+213.2%$723.13M$2.83M-9.5280Analyst ForecastNews CoverageAUTLAutolus Therapeutics2.5518 of 5 stars$2.60+4.4%$10.40+300.0%-58.4%$691.83M$1.70M-2.06330PRTAProthena1.6218 of 5 stars$12.85+0.5%$61.83+381.2%-58.8%$691.45M$133.35M-5.16173Analyst ForecastNews CoverageOCSOculis1.6423 of 5 stars$17.05-0.2%$29.20+71.3%+57.2%$690.59M$980,000.00-8.852CGEMCullinan Therapeutics1.8003 of 5 stars$11.86+0.9%$31.67+167.0%+32.7%$690.58M$18.94M-4.1430News CoverageTECXTectonic Therapeutic2.9296 of 5 stars$46.53+2.6%$72.25+55.3%N/A$686.46MN/A-7.70120Positive NewsTRDAEntrada Therapeutics2.5961 of 5 stars$18.26+3.4%$25.67+40.6%+17.3%$683.29M$129.01M11.11110Gap DownABUSArbutus Biopharma2.551 of 5 stars$3.53+1.4%$5.50+55.8%+45.2%$668.90M$18.14M-8.0973Positive News Related Companies and Tools Related Companies EOLS Competitors RAPP Competitors DNTH Competitors AUTL Competitors PRTA Competitors OCS Competitors CGEM Competitors TECX Competitors TRDA Competitors ABUS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HURA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HURA Stock Alerts